SG Americas Securities LLC Increases Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

SG Americas Securities LLC lifted its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 96.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 151,482 shares of the biopharmaceutical company’s stock after acquiring an additional 74,433 shares during the quarter. SG Americas Securities LLC owned 0.08% of Esperion Therapeutics worth $333,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics in the 3rd quarter worth approximately $27,000. Versor Investments LP bought a new stake in shares of Esperion Therapeutics in the third quarter worth $44,000. Boomfish Wealth Group LLC increased its position in Esperion Therapeutics by 17.1% during the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 5,102 shares during the last quarter. Summit Wealth Group LLC purchased a new stake in Esperion Therapeutics during the third quarter valued at $66,000. Finally, Eaton Financial Holdings Company LLC bought a new position in Esperion Therapeutics in the third quarter valued at about $73,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ESPR. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target on the stock. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.25.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR opened at $1.88 on Wednesday. The company has a market capitalization of $370.44 million, a P/E ratio of -2.94 and a beta of 1.01. Esperion Therapeutics, Inc. has a 1-year low of $1.58 and a 1-year high of $3.94. The firm’s 50 day simple moving average is $2.38 and its two-hundred day simple moving average is $2.14.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $51.63 million for the quarter, compared to the consensus estimate of $55.44 million. During the same quarter last year, the business posted ($0.37) EPS. On average, sell-side analysts anticipate that Esperion Therapeutics, Inc. will post -0.28 earnings per share for the current fiscal year.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.